Clinica Chimica Acta最新文献

{"title":"The potential of circulating free DNA of methylated IGFBP as a biomarker for type 2 diabetes Mellitus: A Comprehensive review","authors":"Audrey Belinda ,&nbsp;Farizky Martriano Humardani ,&nbsp;Sulistyo Emantoko Dwi Putra ,&nbsp;Bhanu Widyadhana","doi":"10.1016/j.cca.2024.120104","DOIUrl":"10.1016/j.cca.2024.120104","url":null,"abstract":"<div><div>T2DM detection methods are commonly used in teens and adults but are generally unsuitable to unborn fetuses in the context of non-invasive prenatal testing (NIPT). Biophysical and biochemical tests for fetuses are often invasive, carry risks, and have low sensitivity and specificity, with no direct method available to diagnose T2DM in utero. In contrast, cell-free DNA (cfDNA) is known have high sensitivity (93–98 %) and specificity (94–100 %) for cancer detection and fetal genetic disorders (trisomy 21, 8, and 13) making it applicable for fetal epigenetic and genetic analysis, including T2DM early detection. However, no study has explored its use for this purpose. Our review focuses on the potential of IGFBP methylation levels in cfDNA as biomarkers for NIPT of T2DM. Placental global hypomethylation in GDM may predict T2DM during the prenatal period, and a similar pattern potentially be detected in cfDNA. Targeted genes reliable for NIPT, such as IGFBPs are needed because their significant role in T2DM and GDM. Among these, IGFBP-1 and IGFBP-2 have shown potential as predictive genes, exhibiting hypermethylation in placental tissue from GDM cases. This hypermethylation reduces their expression and the formation of the IGF-1-IGFBP complex, leading to increased levels of free IGF-1, which is associated with T2DM in the fetus. Hypermethylation regions have longer fragment sizes in cfDNA, thus in T2DM cases, hypermethylation of IGFBP-1 and IGFBP-2 from fetus results in longer cfDNA fragments. Therefore, analyzing the methylation levels and fragment sizes of IGFBP-1 or IGFBP-2 cfDNA could be a promising biomarker for identifying fetal T2DM risk non-invasively.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120104"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR-Cas12a-based detection and differentiation of Mycobacterium spp","authors":"Peeraphan Compiro,&nbsp;Nantinee Chomta,&nbsp;Juthamas Nimnual,&nbsp;Samitanan Sunantawanit,&nbsp;Sunchai Payungporn,&nbsp;Suwatchareeporn Rotcheewaphan,&nbsp;Pornchai Keawsapsak","doi":"10.1016/j.cca.2024.120101","DOIUrl":"10.1016/j.cca.2024.120101","url":null,"abstract":"<div><div><em>Mycobacterium</em> species cause several vital human diseases, including tuberculosis and non-tuberculous mycobacterial infections, which are treated with different drug regimens Therefore, accurate and rapid diagnosis is essential for effective treatment and controlling the spread of these pathogens. This study aims to develop an isothermal method combining RPA and CRISPR-Cas12a techniques, named as MyTRACK, to detect and differentiate major clinical mycobacteria at the species level. The assay has no cross-reactivity with limit of detection of 1 to 100 copies/reaction for various targeted mycobacteria. The results demonstrated 100 % specificity and 92.59 % to 100 % sensitivity in clinical isolates and were consistent with the culture technique with LPA for clinical samples. The MyTRACK assay is an effective, portable, rapid, and accurate screening method for mycobacterial detection and identification, especially in low-resource clinical settings.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120101"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VEGF in psoriatic arthritis: Systematic review and meta-analysis","authors":"Biagio Di Lorenzo ,&nbsp;Stefano Zoroddu ,&nbsp;Arduino A. Mangoni ,&nbsp;Panagiotis Paliogiannis ,&nbsp;Gian Luca Erre ,&nbsp;Rosanna Satta ,&nbsp;Ciriaco Carru ,&nbsp;Angelo Zinellu","doi":"10.1016/j.cca.2024.120084","DOIUrl":"10.1016/j.cca.2024.120084","url":null,"abstract":"<div><div>Psoriatic arthritis (PsA), a chronic autoimmune disease of unclear aetiology, is associated with dysregulated angiogenesis due to the proliferation, migration, and differentiation of endothelial cells. Vascular endothelial growth factor (VEGF) plays a key role such that PsA patients exhibit skin and joint symptoms, e.g., pain and stiffness, with morphologic alterations in blood vessels. To more fully examine this phenomenon, a systematic review and meta-analysis compliant with the PRISMA guidelines (PROSPERO CRD42024572653) was conducted using subgroup and meta-regression analyses. Secondary analyses on disease activity and response to treatment were also included. In the twelve selected studies, VEGF was significantly higher in PsA vs healthy controls (SMD = 0.544, 95 % CI 0.253–0.835;<!--> <!-->p &lt; 0.001) with moderate heterogeneity across studies. Subgroup analysis revealed that the SMD in prospectively conducted studies was significantly higher vs those conducted retrospectively (p = 0.005). Furthermore, methotrexate or sulfasalazine treatment did not affect VEGF which remained significantly higher than controls. Moreover, VEGF was lower in those with inactive disease and in those receiving disease modifying agents in pre-post studies. These findings suggest that VEGF is a promising candidate biomarker in PsA and worthy of further prospective studies to investigate its utility in monitoring disease progress and response to treatment.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120084"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardization of hemoglobin A2 and hemoglobin F: Achievements and perspectives","authors":"Andrea Mosca ,&nbsp;Cristian Arsene ,&nbsp;Renata Paleari ,&nbsp;Patricia Kaiser ,&nbsp;Kees Harteveld ,&nbsp;Yvonne Daniel ,&nbsp;Chie Amano ,&nbsp;Atsushi Murakami ,&nbsp;Guy Auclair ,&nbsp;on behalf of the IFCC-ICSH Joint Working Group for the Standardization of HbA2 and of the IFCC Working Group for the Standardization of HbF","doi":"10.1016/j.cca.2024.120087","DOIUrl":"10.1016/j.cca.2024.120087","url":null,"abstract":"<div><div>The establishment of reference systems for the standardization of hemoglobin A₂ (HbA₂) and fetal hemoglobin (HbF), both critical for improving diagnostic accuracy in conditions such as β-thalassemia and sickle cell disease, are described. Efforts were led by the IFCC and other groups to address and reduce the variability in laboratory measurements of these hemoglobins. This document outlines the production of certified reference materials (CRMs) for HbA₂ and the development of a reference measurement procedure using isotope dilution mass spectrometry. Similarly, standardizing HbF is essential for supporting diagnostic and therapeutic strategies, particularly in managing sickle cell disease. HbF levels can predict disease outcomes and guide treatment plans. Significant challenges remain in achieving consistent measurement across laboratories, and the process for standardization for this minor hemoglobin has just begun. We are confident that the implementation of these reference systems will provide improved accuracy and traceability in the future.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120087"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-based real-time quality control integrating neural networks and joint probability analysis","authors":"Yong Xia ,&nbsp;Wenbo Zheng ,&nbsp;Hao Xue ,&nbsp;Minxuan Feng ,&nbsp;Qinxin Zhang ,&nbsp;Bowen Li ,&nbsp;Xin Li ,&nbsp;Huan Qi ,&nbsp;Yan Liu ,&nbsp;Tony Badrick ,&nbsp;Lei Zheng ,&nbsp;Ling Ji","doi":"10.1016/j.cca.2024.120112","DOIUrl":"10.1016/j.cca.2024.120112","url":null,"abstract":"<div><h3>Objective</h3><div>Patient-based real-time quality control (PBRTQC) utilizes patient test results to continuously monitor laboratory test quality, addressing issues like discontinuities and matrix effects of traditional internal quality control. However, its clinical performance still requires enhancement. This study combined neural networks (NN) and joint probability analysis (NN-PBRTQC) to improve the clinical performance of PBRTQC.</div></div><div><h3>Methods</h3><div>Data were collected from Peking University Shenzhen Hospital and Nanfang Hospital Southern Medical University, which included a series of analytes. A neural network model was trained to predict the test results by integrating patient demographics. Residuals between the expected and actual test results were inputs for statistical process control algorithms to monitor analytical errors. Additionally, an intelligent alarm system using joint probability analysis was developed to reduce the false alarm rate (FAR). The performance of NN-PBRTQC was evaluated using FAR, and the number of patients until error detection was compared to traditional PBRTQC.</div></div><div><h3>Results</h3><div>NN-PBRTQC significantly enhanced the clinical performance of PBRTQC. Under the same desired FAR (DFAR) of 0.1 %, NN-PBRTQC required 64 % fewer samples for error detection than traditional PBRTQC for the analytes, which improved the sensitivity of error detection.</div></div><div><h3>Conclusion</h3><div>NN-PBRTQC provides a novel method for PBRTQC, effectively addressing sample variations and false alarms. It significantly reduces the false alarm rate and the sample size required for error detection, accelerating the implementation of PBRTQC in laboratories.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120112"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A model based on chitinase 3-like protein for expecting liver severity of hepatitis B virus infections in the immune tolerance phase","authors":"Jia-Lan Wang ,&nbsp;Su-Wen Jiang ,&nbsp;Ai-Rong Hu ,&nbsp;Xiao-Jun Shi ,&nbsp;Ai-Wu Zhou ,&nbsp;Ken Lin ,&nbsp;Ying Fan ,&nbsp;Meng-Han Jin ,&nbsp;Hao-Jin Zhang","doi":"10.1016/j.cca.2024.120085","DOIUrl":"10.1016/j.cca.2024.120085","url":null,"abstract":"<div><h3>Background</h3><div>The question of whether to treat patients with chronic hepatitis B (CHB) during the immune tolerance (IT) period is a matter of ongoing debate, as it is difficult to discern different levels of liver disease severity. We created and assessed a novel diagnostic model for identifying significant liver tissue damage in individuals with CHB in IT phase.</div></div><div><h3>Methods</h3><div>From November 2018 to December 2022, a cross-sectional study of 311 patients with chronic hepatitis B virus infection (HBV DNA &gt; 30 IU/mL) at Ningbo No. 2 Hospital, Ningbo, China, who underwent liver biopsy, including 44 patients in IT phase. Utilizing univariate regression analyses and logistics analysis, and model was developed and validated to predict the severity of hepatic inflammatory and fibrosis in CHB patients and in IT phase.</div></div><div><h3>Results</h3><div>Chitinase 3-like Protein (CHI3L1), albumin (ALB), alanine transaminase (ALT) / aspartate aminotransferase (AST) were identified as independent predictors of liver lesion severity in CHB patients with IT. The three were combined to build the model (named as CAA index), which demonstrated good performance. The CAA index achieved an area under the receiver operating characteristic curve (AUC) of 0.916 (95 % CI, 0.820–1.000) and AUC of validation group was 0.875 (95 % CI, 0.683–1.000).</div></div><div><h3>Conclusions</h3><div>CHI3L1 serves as an independent measure of liver fibrosis and inflammation in CHB. This diagnostic model has some value in assessing the severity of the patient’s liver lesion severity and may be a reliable non-invasive diagnostic model helping determine whether treatment is necessary among CHB patients in IT phase.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120085"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nomogram model for predicting advanced liver fibrosis in patients with hepatitis B: A multicenter study","authors":"Bo Hu ,&nbsp;Li Yang ,&nbsp;Rui-Bing Li ,&nbsp;Jiao Gong ,&nbsp;Er-Hei Dai ,&nbsp;Wei Wang ,&nbsp;Fa-Quan Lin ,&nbsp;Chang-Min Wang ,&nbsp;Xiao-Li Yang ,&nbsp;Ying Han ,&nbsp;Xiao-Long Qi ,&nbsp;Jing Teng ,&nbsp;Ya-Jie Wang ,&nbsp;Cheng-Bin Wang","doi":"10.1016/j.cca.2024.120102","DOIUrl":"10.1016/j.cca.2024.120102","url":null,"abstract":"<div><h3>Background</h3><div>Biopsy is the gold standard method for diagnosing liver fibrosis. FibroScan is a non-invasive method of diagnosing liver fibrosis, but it still faces some limitations. This study aimed to establish a nomogram model and identify patients at high risk of advanced liver fibrosis associated with hepatitis B infection.</div></div><div><h3>Methods</h3><div>Data were collected from 375 patients with hepatitis B who underwent liver biopsy. Patients were divided randomly into the training (n = 263) and validation sets (n = 112). Their demographic and clinical characteristics were analyzed using the least absolute shrinkage and selection operator regression (LASSO). A nomogram model was established to predict the fibrosis stage, and its performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA) and was compared with other recognized models.</div></div><div><h3>Results</h3><div>In total, 209 patients with non-advanced fibrosis (S0-1) and 166 patients with advanced fibrosis (S ≥ 2) were included. Hyaluronic acid (HA), laminin, total cholesterol (TC), platelet, and age were entered into the nomogram model based on the LASSO analysis. The nomogram model for predicting advanced fibrosis exhibited a relatively high AUC in the training set. Compared with FIB4 and APRI, the nomogram model showed a better agreement between the actual status and predicted status based on the calibration curve. The nomogram model showed an AUC similar to FibroScan in the validation cohort, and showed high clinical net benefits in the training and validation sets.</div></div><div><h3>Conclusion</h3><div>Our nomogram model can help identify patients with hepatitis B and advanced liver fibrosis.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120102"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR technology combined with isothermal amplification methods for the diagnosis of Candida albicans infection","authors":"Runde Liu ,&nbsp;Wenxiang Ji ,&nbsp;Min Jiang ,&nbsp;Jilu Shen","doi":"10.1016/j.cca.2024.120106","DOIUrl":"10.1016/j.cca.2024.120106","url":null,"abstract":"<div><div>Since <em>Candida albicans</em>, a type of fungus, causes severe infections that pose a significant threat to human health, its rapid detection is critical in clinical antifungal therapy. Traditional fungal diagnostic approaches are largely based on the culture method. This method is time-consuming and laborious, taking about 48–72 h, and cannot identify emerging species, making it unsuitable for critically ill patients with bloodstream infections, sepsis, and so on. Other antigen or nucleic acid amplification-based methods were also found to be unsuitable for Point-of-Care Testing (POCT) diagnosis due to various limitations. Therefore, establishing a new approach for the rapid diagnosis of Candida spp is imperative. Herein, we proposed a novel diagnostic method for invasive fungi detection. Specifically, we created a new CRISPR diagnostic platform for <em>Candida albicans</em>-specific Internal Transcriptional Spacer 2 (ITS2) gene by combining the DNase cleavage activity of Cas12a with Recombinase Polymerase Amplification (RPA). Furthermore, to achieve rapid on-site detection under low-resource conditions, we used a transverse lateral flow strip with a single target to visualize the Cas12a single enzyme digestion product. We designated the platform as a rapid molecular detection tool that integrates RPA and the CRISPR-Cas12a technology. The entire platform can accurately identify <em>Candida albicans</em> within 50 minwhile remaining unaffected by other fungi or bacteria. Furthermore, the detection limit of the platform could reach 10² CFU/ml. Moreover, this approach offers additional benefits, including easy operation, low set-up cost, and broad applicability for <em>Candida albicans</em> detection across medical institutions at all levels, especially in township health centers in resource-poor regions.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120106"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harmonization of anti-nuclear antibody testing (ANA) by indirect immunofluorescence assay: Results from ten years of UK NEQAS external quality assessment","authors":"Maria Infantino ,&nbsp;Teresa Carbone ,&nbsp;Dina Patel ,&nbsp;Ravishankar Sargur ,&nbsp;Carol Stanley ,&nbsp;Amina Bhayat-Cammack ,&nbsp;Emirena Garrafa ,&nbsp;Silvia Pancani ,&nbsp;Mariangela Manfredi ,&nbsp;Luis E.C. Andrade ,&nbsp;Nicola Bizzaro","doi":"10.1016/j.cca.2024.120088","DOIUrl":"10.1016/j.cca.2024.120088","url":null,"abstract":"<div><div>External quality assurance (EQA) programs play a pivotal role in monitoring laboratory practices, allowing each laboratory to evaluate the consistency of results across different methods as well the ability of individual laboratories to compare and improve over time their own performance.</div><div>The objective of our study was to analyze the UK NEQAS EQA reports for the “Antibodies to Nuclear and Related Antigens” program from 2013 to 2023, to assess the overall level of harmonization of the responses for anti-nuclear antibody (ANA) testing by indirect immunofluorescence (IIF), in terms of both pattern and titer consensus. As a second aim, we analyzed the impact of the introduction in UK NEQAS EQA reports of the International Consensus on ANA Patterns (ICAP) nomenclature and of digital image recognition on the harmonization of the ANA HEp-2 IIF test.</div><div>The percentage of consensus for positive/negative results was significantly higher (90.9 ± 1.4) in 2023 than in 2013 (64.0 ± 7.8, p &lt; 0.001). Common to all years in the investigated period, consensus on pattern recognition was significantly lower for the homogenous pattern (70.5 ± 16.0) compared to the centromere (84.9 ± 14.9), the speckled (90.3 ± 12.3), and the negative (84.5 ± 18.6, p &lt; 0.001) samples, while it was significantly higher for titers 1:80–1:320 than for titers &gt; 1:320 (p &lt; 0.001).</div><div>The difference between manual reading and digital reading was not significant (93.8 % <em>vs</em>. 92.4 %; p = 0.078), but it was significant between the pre- and post-use of the ICAP nomenclature (82.6 % <em>vs</em>. 93.8 %; p &lt; 0.001).</div><div>This study shows that the variability in ANA recognition and reporting is pattern (homogeneous &gt; speckled &gt; centromere) and titer (high titer &gt; low titer) dependent. While we did not find any difference between the use of manual reading compared to digital reading, the adoption of the ICAP nomenclature greatly improved the harmonization of ANA reporting.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120088"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-sensitivity cardiac troponin T and N-terminal b-type natriuretic propeptide are associated with cardiac and all-cause mortality in older adults – A population-based ten-year follow-up study","authors":"Elisa Heikkilä ,&nbsp;Taina Katajamäki ,&nbsp;Marika Salminen ,&nbsp;Kerttu Irjala ,&nbsp;Anna Viljanen ,&nbsp;Marja-Kaisa Koivula ,&nbsp;Kari Pulkki ,&nbsp;Matti Viitanen ,&nbsp;Tero Vahlberg ,&nbsp;Laura Viikari","doi":"10.1016/j.cca.2024.120116","DOIUrl":"10.1016/j.cca.2024.120116","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac troponin T (cTnT) and N-terminal B-type natriuretic propeptide (proBNP) are mainly used as biomarkers to diagnose specific conditions of the heart, but they also have predictive ability. Our aim was to study their associations with cardiovascular and all-cause mortality in an older population in non-acute conditions.</div></div><div><h3>Methods</h3><div>A population-based study with a ten-year follow-up. The data comes from a community-based representative sample of an older population with 1260 participants (participation rate 82 %). Associations were analyzed using Cox proportional hazard models.</div></div><div><h3>Results</h3><div>Altogether, 467 (37%) subjects died during the 10-year follow-up period, and 149 of those of a cardiovascular disease. Both elevated cTnT and proBNP concentrations were statistically significantly associated with cardiovascular and all-cause mortality in older adults.</div></div><div><h3>Conclusions</h3><div>Our study shows that older population with higher cTnT and proBNP concentrations have an increased risk of cardiovascular and all-cause mortality. Acknowledging the elevated risk may aid in targeting follow-up, prevention, and treatment adequately and more individually.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120116"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}